He has a vision for entering the oncology market, which is targeted by multinational pharmaceutical companies, by presenting new business models in the field of cancer treatment based on over 20 years of experience in nanogel research and the commercialization of thrombin factor diagnostic technologies. In addition, he earned his Ph.D. from the Department of Chemistry at Georgia Institute of Technology and received the award for the best doctoral dissertation. Following this, he worked as a research fellow at Harvard Medical School's Springer Lab, where he published papers in prestigious journals such as Nature and PNAS.
Education and Publications
- Ph.D. in Chemistry from Georgia Tech (Best Doctoral Dissertation Award)
- Research Fellow at Harvard Medical School's Springer Lab (publications in Nature, PNAS, etc.)
- CEO of OncoLab
- Published 40 SCI-level papers in journals such as Nature, Nature Communications, PNAS, and JACS, with a total citation index (IF) of 347
Strengths as a Researcher and Founder
-
Outstanding Research Capability
Developed the next-generation immuno-oncology treatment platform ANGel based on over 20 years of experience in nanogel research.
-
Extensive Business Experience
Successfully led the commercialization of thrombin factor diagnostic technologies, building business acumen and know-how.
-
Global Network
Established a favorable position for international market entry through the global network built during his time at Harvard Medical School's Springer Lab.
-
Strong Execution Power
Possesses the drive to successfully connect technology development and commercialization.